ATC Group: M05BX05 Burosumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M05BX05 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M05 Drugs for treatment of bone diseases
3 M05B Drugs affecting bone structure and mineralization
4 M05BX Other drugs affecting bone structure and mineralization
5 M05BX05

Active ingredients in M05BX05

Active Ingredient Description
Burosumab

Burosumab is a recombinant human monoclonal antibody (IgG1) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). By inhibiting FGF23, burosumab increases tubular reabsorption of phosphate from the kidney and increases serum concentration of 1, 25 dihydroxy-Vitamin D.

Related product monographs

Title Information Source Document Type  
CRYSVITA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
CRYSVITA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.